Belgium Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Dec. 1, 2006 - 68 Pages

Table of Contents

Chapter 1 - Executive Summary

Belgium Pharmaceuticals & Healthcare Industry SWOT

Belgium Economic SWOT

Chapter 2 - Belgium: Business Environment Ranking

Western Europe

Table: Western Europe Business Environment Rankings

Business Environment Ranking

Economics - Long Term risk

Politics - Long Term risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - Belgium: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Developments

Pricing & Reimbursement Issues

Chapter 5 - Industry Developments

Healthcare sector

Table: Healthcare Budget In Belgium (US$bn)

Pharmaceuticals Sector

Solvay

UCB Pharma

Omega Pharma

Other Company Developments

R&D Sector

Generics Sector

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: Belgium Drug Market Forecast Indicators

Key Growth Factors - Industry

Key Growth Factors - Macroeconomic

Table: Belgium - Macroeconomic Forecasts

Prescription Market Forecast

Table: Belgium Prescription Drugs Market Forecast Indicators

OTC Market Forecast

Table: Belgium OTC Drugs Market Forecast Indicators

Generics Market Forecast

Table: Belgium Generics and Branded Drug Market Forecast Indicators

Export/Import Forecasts

Table: Belgium Pharmaceuticals Exports & Imports Forecasts

Other Healthcare Data Forecasts

Table: Belgium Healthcare Data Forecast Indicators

Belgium Pharmaceuticals & Healthcare Report Q3 2006

Chapter 7 - Competitive Landscape

Table: Leading Pharmaceutical Company Sales in Belgium, 2004-05

Chapter 8 - Company Monitor

Leading Multinational Manufacturers

GlaxoSmithKline (GSK)

Pfizer

Novartis

Sanofi-Aventis

Merck & Co

Janssen Pharmaceutica

Leading Indigenous Manufacturers

UCB Pharma

Solvay

Chapter 9 - BMI Forecast Modelling

How we generate our industry forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 10 - Appendix: Regional Demographic Data

Wages (ave. labour force per annum), US$ PPP

Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Chapter 11 - Country Snapshot: Belgium Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption and Stratification

Abstract

Belgium's pharmaceuticals market is characterised by high per capita spend, low generic penetration and widespread cost-cutting measures. Because it is a mature market, growth opportunities are limited, but an informed patient population is driving the uptake of the latest technologies and medications. The value of the pharmaceutical market is currently US$4.7bn, and 5% y-o-y growth is forecast through to 2010.

Many multinationals use Belgium as an international distribution centre, meaning that import/export trade in pharmaceutical products far exceeds the value of the domestic market. In addition, the country is a major manufacturing hub, particularly for biopharmaceuticals. Both GlaxoSmithKline Biologicals and Solvay have vaccine production capabilities in Belgium.

BMI's adjusted Business Environment Rankings for Western Europe reveal that Belgium places seventh, just ahead of the Netherlands. The country scores highly for low political and economic risk and also for market growth potential, but is let down by market size and domestic sector threat.

On the back of robust first half 2006 financial results, Belgian pharmaceutical and chemical group Solvay intends to expand its reach in its faster growing markets, specifically in Asia, NAFTA and in Mercosur - a South American free trade association. Meanwhile, compatriot firm UCB Pharma's potential Crohn's disease blockbuster Cimzia (anti-TNF alpha antibody) is on track to be submitted for approval in the first half of 2007. If approved and launched, the drug will represent a major advance in the treatment of the debilitating disease.

A reference pricing system was introduced in 2001 to encourage the wider dispensing of generic drugs. Under the scheme, pharmaceuticals are reimbursed on the basis of the price of the generic drug, which was initially set at 16% less than that of the equivalent branded product. Over time, the Belgian Government has progressively reduced the reference price from 84% (until July 2002), 80% (until January 2003) to 74% of the price of the originator medicine (at July 2005). The rate now stands at 30% below that of the equivalent branded product.

Key Benefits of Report

Rely On Our Independent 5-Year Forecasts As A Benchmark
to test other views - a key input for successful budgetary and strategic business planning.

Target Business Opportunities & Risks
through our reviews of latest industry trends, regulatory changes, and major deals, projects and investments

Exploit Latest Competitive Intelligence & Company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure - includes multinational and national companies.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.